Prestige Consumer Healthcare (NYSE:PBH) Announces Earnings Results, Beats Expectations By $0.04 EPS

Prestige Consumer Healthcare (NYSE:PBH) released its quarterly earnings results on Thursday. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04, Zacks reports. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare updated its FY 2025 guidance to 4.500-4.500 EPS.

Prestige Consumer Healthcare Stock Performance

Shares of Prestige Consumer Healthcare stock traded up $11.11 during trading on Thursday, hitting $87.21. 768,028 shares of the stock were exchanged, compared to its average volume of 306,855. Prestige Consumer Healthcare has a 1-year low of $60.00 and a 1-year high of $87.39. The stock has a market capitalization of $4.31 billion, a price-to-earnings ratio of 21.22, a price-to-earnings-growth ratio of 2.15 and a beta of 0.50. The company has a fifty day moving average price of $79.13 and a 200-day moving average price of $75.26. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61.

Insider Buying and Selling

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Adel Mekhail sold 9,063 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total value of $743,166.00. Following the transaction, the executive vice president now directly owns 18,365 shares in the company, valued at $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,810 shares of company stock worth $3,187,300. Company insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on PBH shares. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a report on Monday, December 9th. DA Davidson restated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Finally, Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $85.25.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.